Multiple Sclerosis

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

The results echo the previous understanding of MS specialists as well as add to the literature that has been collected thus far from other assessments.

Recent studies show efficacy and safety for both lemborexant and ozanimod.

Ponesimod reduced fatigue-related symptoms in phase 3 clinical trial.

Hospitals are preparing to treat MS patients safely in the wake of fears over the global pandemic.

MS patients who experience relapses score significantly lower on the Timed 25-Foot Walk Test.

A recent review of claims data from 2006-2016 revealed out-of-pocket costs for patients have increased seven-fold during the 10-year period, from $372 to $2673 annually.

Recent study shows that obesity appears to be associated with an increased pediatric MS risk and that obese patients did not respond well to first-line medications.

What new drug classes are catching the most traction among clinicians?

It may not be the glitziest addition to screening tools, but MRIs have stood out as a care-changing resource.

The role of a primary care physician in multiple sclerosis care should be minimal.

What is the role of a primary care physician in treating later-onset multiple sclerosis?

How advanced biologic care and symptom management programs fail patients more advanced in their disease.

When onset occurs before the age of 18, multiple sclerosis causes more severe cognitive impairment than in equivalent adult-onset cases.

The first-approved therapy for what clinicians once called the 'chronic' form of multiple sclerosis has changed standards of care.

Why biomarkers must be identified in patients with the progressive form of multiple sclerosis—and in what symptoms may those biomarkers best present.

New research shows families of children with pediatric onset multiple sclerosis face a series of challenges, both before and after diagnosis.

Mavenclad will be marketed as a short-term oral drug option for relapsing-remitting multiple sclerosis, but it also carries malignancy risks.

Siponimod becomes first oral drug to treat secondary progressive MS to receive FDA approval.

Patients who drank two cans of soda per day were 5 times more likely to have severe symptoms than those who "seldom" consumed it.

A new study of more than 300000 women finds their may be a link between higher BMI at puberty and development of MS.

Rehabilitative approaches seem promising for managing cognitive problems in multiple sclerosis.

New research suggests that in the era of disease-modifying therapies, women with multiple sclerosis face no heightened risks of relapse after pregnancy.

In a rare clinical trial, stem cell transplantation appeared to provide greater protection against MS progression than DMT.

A new report shows that multiple sclerosis diagnoses have steadily risen in older patients in the past 5 years, bucking previous patient rate estimates.

Anxiety and depression each contribute to impaired cognition in patients with MS and other immune-mediated disorders, a new study shows.

Behavioral model predicts when MS patients decline treatment for delayed or insufficient benefit, and the probability and severity of side effects.

The known medium of communication between the immune system and central nervous system, metabolites could believably play a role in the multiple sclerosis disease course.

Early findings indicate that Sephin1 could lead to better clinical outcomes in MS patients as a safe, neuroprotective drug.

A novel bioequivalent of dimethyl fumarate (Tecfidera) may soon be offering another treatment option for patients with multiple sclerosis.